natgillin/translations-raw huggingface dataset:
• complicated (difficult to treat) infections of the urinary tract (structures that carry urine), including pyelonephritis (kidney infection);
• tüsistunud (raskelt ravitavad) kuseteede nakkused, sealhulgas püelonefriit (neeruinfektsioon);
Zavicefta contains the active substances ceftazidime and avibactam.
Zavicefta sisaldab toimeainetena tseftasidiimi ja avibaktaami.
In the first study, one of the patient groups studied showed 92% of patients (376 out of 410) treated with Zavicefta and metronidazole were cured, compared with 93% (385 out of 416) of patients treated with meropenem.
Esimeses uuringus paranes Zavicefta ja metronidasooliga ravitud patsientidest 92% (376 patsienti 410st) ning meropeneemiga ravitud patsientidest 93% (385 patsienti 416st).
How does Zavicefta work?
Kuidas Zavicefta toimib?
Zavicefta is available as a powder to be made up into a solution for infusion (drip) into a vein.
Zaviceftat turustatakse infusioonilahuse (veeni tilgutatava lahuse) pulbrina.
What benefits of Zavicefta have been shown in studies?
Milles seisneb uuringute põhjal Zavicefta kasulikkus?
• complicated (difficult to treat) infections of the tissues and organs within the belly (intra-abdominal infections);
• tüsistunud (raskelt ravitavad) kõhuõõne kudede ja elundite infektsioonid (kõhuõõnenakkused);
Ceftazidime is an antibiotic called a cephalosporin, which belongs to the wider group ‘beta-lactams'.
Tseftasidiim on beetalaktaamide rühma kuuluv antibiootikum tsefalosporiin, mis takistab bakteri rakumembraani oluliste komponentmolekulide teket.
Avibactam blocks the action of bacterial enzymes called beta-lactamases.
Avibaktaam blokeerib bakteriensüümide beetalaktamaaside toime.
International non-proprietary name (INN): abetimus
Rahvusvaheline mittekaubanduslik nimetus (INN): abetiimus
What is Riquent?
Mis on Riquent?
Following the CHMP's opinion, it usually takes around 2 months for the European Commission to grant a licence.
kasutatavate ravimite komitee arvamuse järel kulub tavaliselt ligikaudu 2 kuud, enne kui Euroopa Komisjon müügiloa väljastab.
If you are in a clinical trial and need more information about your treatment, contact the doctor who is giving it to you.
Kui te osalete kliinilises uuringus ja vajate ravi kohta lisateavet, võtke ühendust arstiga, kes teile ravi määras.
The application was at day 114 when the company withdrew.
Taotlust oli menetletud 114 päeva, kui ettevõte taotluse tagasi võttis.
The letter from the company notifying the EMEA of the withdrawal of the application is available here.
Ettevõtte taotluse tagasivõtmise avaldus EMEA-le on kättesaadav siin.
A compassionate use programme is a programme through which doctors can request a medicine for a specific disease for one of their patients before the medicine is fully authorised.
Eriloaga kasutamise programm on programm, mille kaudu arstid võivad taotleda ravimi kasutamist mõnel patsiendil teatava haiguse ravimiseks enne ravimile täieliku müügiloa andmist.
Riquent is a solution for injection that contains 50 mg/ml of the active substance abetimus.
Riquent on süstelahus, mis sisaldab toimeainena 50 mg/ml abetiimust.
The CHMP was evaluating the initial documentation provided by the Company and had not yet made any recommendations.
Inimtervishoius kasutatavate ravimite komitee hindas ettevõtte esitatud esmaseid dokumente ega olnud veel soovitusi andnud.
Abetimus is a small piece of double-stranded DNA that has been designed to reduce circulating levels of these antibodies.
Abetiimus on väike kaksikahelalise DNA lõik, mille eesmärk on vähendada nende antikehade taset vereringes.
Abetimus, the active substance in Riquent, is a selective immunosuppressive agent (a compound that selectively dampens down the immune system).
Riquenti toimeaine abetiimus on selektiivne immunosupressant (selektiivselt immuunsüsteemi pärssiv ühend).
On 13 October 2006, La Jolla Limited officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for Riquent, for the treatment of lupus nephritis.
2006. aasta 13. oktoobril teatas ettevõte La Jolla Limited ametlikult inimtervishoius kasutatavate ravimite komiteele oma otsusest võtta tagasi ravimi Riquent müügiloa taotlus.
Because the number of patients with lupus nephritis is low, the disease is rare, and Riquent was designated an orphan medicine (a medicine used in rare diseases) on 20 November 2001.
Kuna luupusnefriidiga patsiente on vähe, on see haigus harvaesinev ja Riquent tunnistati 20. novembril 2001 harva kasutatavaks ravimiks.
There were two main studies involving a total of 529 patients with SLE, in which Riquent was compared with a placebo (a dummy treatment).
Kahes peamises kliinilises uuringus, milles osales kokku 529 süsteemse erütematoosluupusega patsienti, võrreldi Riquenti platseeboga (näiv ravim).
These antibodies are thought to be linked to the development of lupus kidney disease.
Need antikehad arvatakse olevat seotud luupusneeruhaiguse kujunemisega.
When Riquent is injected, the levels of these antibodies in the blood are lowered and this is expected to help reduce the patient's likelihood of experiencing a ‘flare'.
Riquenti süstimisel nende antikehade tasemed veres alanevad ja see aitab eeldatavasti vähendada haiguse ägenemise tõenäosust patsiendil.
What are the consequences of the withdrawal for patients undergoing clinical trials / compassionate use programmes with Riquent?
Millised on taotluse tagasivõtmise tagajärjed praegu Riquenti kliinilistes uuringutes või eriloaga kasutamise programmides osalevatele patsientidele?
What documentation did the company present to support its application to the CHMP?
Milliseid dokumente esitas ettevõte inimtervishoius kasutatavate ravimite komiteele tehtud taotluse toetuseks?
Riquent was expected to be used to treat lupus nephritis, an inflammation of the kidneys in patients with systemic lupus erythematosus (SLE, an auto-immune disease caused by the body's own defence system attacking normal tissue) who have a history of kidney disease and have been tested to check that they will benefit from the medicine.
Riquenti kavandati kasutada luupusnefriidi raviks, mis on süsteemse erütematoosluupusega (autoimmuunhaigus, mille puhul keha kaitsemehhanism ründab normaalseid kudesid) patsientidel esinev neerupõletik, kui patsientidel on varem esinenud neeruhaigus ja on kontrollitud ravimi kasulikkust neile.
Most patients with SLE have antibodies in their blood that are directed against double-stranded DNA (deoxyribonucleic acid).
Enamikul süsteemse erütematoosluupusega patsientidel on veres kaksikahelalise DNA (desoksüribonukleiidhappe) vastu suunatud antikehad.
Riquent was expected to delay and to reduce the incidence of ‘flares' (increased signs of kidney disease).
Riquenti kavandati kasutada ägenemiste (neeruhaiguse nähtude tugevnemine) edasilükkamiseks ja vähendamiseks.
The company informed the CHMP that it plans to continue the ongoing clinical trials in the treatment of lupus nephritis.
Ettevõte teavitas inimtervishoius kasutatavate ravimite komiteed, et ta kavatseb pooleliolevad kliinilised uuringud luupusnefriidi ravi kohta lõpetada.
Ref. EMEA/410799/2006
London, 18. oktoober 2006 Viitedokument EMEA/435974/2006
The studies measured how many patients developed ‘flares' and the time to the development of the flares by measuring the levels of protein in the urine and of creatinine (an enzyme that is a marker of kidney function) in the blood.
Uuringutes mõõdeti, mitmel patsiendil haigus ägenes ning kui palju kulus aega haiguse ägenemiseni, mõõtes valgu taset uriinis ja vere kreatiniinitaset (neerufunktsiooni markerina kasutatav ensüüm).
The Company has no compassionate use programme.
Ravimi eriloaga kasutamise programmi ettevõttel ei ole.
What was Riquent expected to be used for?
Milleks kavandati Riquenti kasutada?
The effects of Riquent were first tested in experimental models before being studied in humans.
Enne uuringuid inimestel kontrolliti Riquenti toimet katsemudelites.
How is Riquent expected to work?
Milline on Riquenti eeldatav toime?
QUESTIONS AND ANSWERS ON THE WITHDRAWAL OF THE MARKETING APPLICATION for RIQUENT
TEAVE MÜÜGILOA TAOTLUSE TAGASIVÕTMISE KOHTA
The CHMP was evaluating the initial documentation provided by the company.
Inimtervishoius kasutatavate ravimite komitee hindas sel ajal ettevõtte esitatud esmaseid dokumente.
This summary was last updated in 10-2010.
Kokkuvõtte viimane uuendus: 10-2010.
The European Commission granted a marketing authorisation valid throughout the European Union for Caelyx on 21 June 1996.
Euroopa Komisjon andis Caelyxi müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 21. juunil 1996.
The marketing authorisation holder is Janssen-Cilag International NV.
Müügiloa hoidja on Janssen-Cilag International NV. Müügiluba on tähtajatu.
Doxorubicin hydrochloride has been available since the 1960s.
Doksorubitsiinvesinikkloriidi on turustatud alates 1960. aastatest.
It contains the active substance doxorubicin hydrochloride (2 mg/ml).
See sisaldab toimeainena doksorubitsiinvesinikkloriidi (2 mg/ml).
The full EPAR for Caelyx can be found on the Agency's website ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Euroopa avaliku hindamisaruande täistekst Caelyxi kohta on ameti veebilehel: EMA website/Find medicine/Human medicines/European Public Assessment Reports.
The additional studies showed that Caelyx was also more effective than the comparator combinations.
Täiendavad uuringud näitasid, et Caelyx on efektiivsem kui võrdlusravimite kombinatsioonid.
The CHMP decided that Caelyx's benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Caelyxi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda müügiloa.
Other very common side effects include palmar-plantar erythrodysaesthesia syndrome (redness and pain on the hands and feet), vomiting, stomatitis (inflammation of the lining of the mouth), rash, asthenia (weakness), low blood cell counts, loss of appetite, alopecia (hair loss), fatigue (tiredness), diarrhoea, constipation and mucositis (inflammation of the mouth and throat).
Muud väga sagedad kõrvalnähud on palmaar-plantaarse erütrodüsesteesia sündroom (käe- ja jalalabade punetus ja valu), oksendamine, stomatiit (suu limaskesta põletik), lööve, asteenia (nõrkus), vererakkude vähesus, isutus, alopeetsia (juuste väljalangemine), väsimus, kõhulahtisus, kõhukinnisus ja mukosiit (suu- ja kõripõletik).
Other information about Caelyx
Muu teave Caelyxi kohta
For Kaposi's sarcoma, around 70% of the patients had a complete or partial response to treatment, with similar results in the study of patients who had been treated before.
Kaposi sarkoomi ravis tekkis täielik või osaline ravivastus ligikaudu 70%-l patsientidest ja samasugused tulemused saadi ka uuringus varem ravitud patsientidega.
For Kaposi's sarcoma, the dose is 20 mg/m2 every two to three weeks for two to three months, and for multiple myeloma, it is 30 mg/m2 on day four of each three-week cycle of bortezomib treatment, for as long as the patient continues to benefit from the treatment and can tolerate it.
Kaposi sarkoomi korral on annus 20 mg/m2 iga 2-3 nädala järel kahe kuni 3 kuu jooksul ning hulgimüeloomi korral 30 mg/m2 Caelyxit bortesomiibi iga kolmenädalase ravitsükli 4. päeval, kuni ravist on patsiendile kasu ja ta seda talub.
However, patients receiving Caelyx were less likely to experience heart problems.
Caelyxit kasutanud patsientidel oli südamehäirete tekkimine vähem tõenäoline.
It also reduces its effects on non-cancer tissues and cells, so it is less likely to cause some side effects.
See vähendab ka toimet vähita kudedele ja muudele kui vähirakkudele, mis vähendab kõrvalnähtude tekkimise tõenäosust.
The main measure of effectiveness was time until the disease got worse or, for Kaposi's sarcoma, the number of patients who responded to treatment.
Efektiivsuse põhinäitaja oli haiguse süvenemiseni kulunud aeg või Kaposi sarkoomi korral ravivastusega patsientide arv.
For more information about treatment with Caelyx, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Kui vajate Caelyxiga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
Caelyx is used to treat the following types of cancer in adults:
Caelyxit kasutatakse järgmiste vähivormide ravimiseks täiskasvanuil:
The recommended starting dose of Caelyx for breast or ovarian cancer is 50 mg per square metre body surface area (calculated using the patient's height and weight) every four weeks for as long as the disease does not get worse and the patient can tolerate the treatment.
Caelyxi soovituslik algannus rinna- või munasarjavähiga naistele on 50 mg kehapindala ruutmeetri kohta (arvutatakse patsiendi pikkuse ja kaalu järgi) iga 4 nädala järel, kuni haigus ei süvene ja patsient talub ravi.
This is a summary of the European public assessment report (EPAR) for Caelyx.
Käesolev dokument on ravimi Caelyx Euroopa avaliku hindamisaruande kokkuvõte.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Caelyx.
Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
Further studies compared Caelyx with the combination of doxorubicin, bleomycin and vincristine (other anticancer medicines) in 258 patients and with the combination of bleomycin and vincristine in 241 patients.
Täiendavates uuringutes võrreldi Caelyxit doksorubitsiini, bleomütsiini ja vinkristiini kombinatsiooniga (samuti vähiravimid) 258 patsiendil ning bleomütsiini ja vinkristiini kombinatsiooniga 241 patsiendil.
In the treatment of breast cancer, Caelyx was as effective as standard doxorubicin: the time until the disease got worse was around 7.5 months in both groups.
Rinnavähi ravis oli Caelyx sama efektiivne kui tavaline doksorubitsiin: haiguse süvenemiseni kulus mõlemas rühmas ligikaudu 7,5 kuud.
For AIDS-related Kaposi's sarcoma, the effectiveness of Caelyx was studied in two main studies involving 384 patients, including 77 who had received treatment before.
AIDSiga seotud Kaposi sarkoomi ravis uuriti Caelyxi efektiivsust kahes põhiuuringus, milles osales 384 patsienti, kellest 77 olid varem ravi saanud.
Caelyx doxorubicin hydrochloride
Caelyx doksorubitsiinvesinikkloriid
• Kaposi's sarcoma (a cancer of the blood vessels) in patients with acquired immune deficiency syndrome (AIDS) who have very damaged immune systems and extensive sarcoma on the skin, the moist body surfaces or the internal organs;
• Kaposi sarkoom (veresoonte teatud vähk) omandatud immuunpuudulikkuse sündroomiga (AIDS) patsientidel, kellel on tugevasti kahjustatud immuunsüsteem ja nahal, limaskestal või siseelunditel ulatuslik sarkoom;
• multiple myeloma (a cancer of the cells in the bone marrow), in patients with progressive disease who have received at least one other treatment in the past and have already undergone or are unsuitable for a bone marrow transplant.
• hulgimüeloom (luuüdi rakkude teatud vähk) progresseeruva haigusega patsientidel, kes on varem saanud vähemalt ühte muud liiki ravi ja kellele on luuüdi juba siiratud või kellele seda ei saa siirata.
The most common side effect seen in all types of cancer (in more than 1 patient in 10) is nausea (feeling sick).
Kõigi vähiliikide korral on kõige sagedam kõrvalnäht (esinenud enam kui 1 patsiendil 10st) iiveldus.
For metastatic breast cancer, Caelyx has been compared with standard doxorubicin in one main study involving 509 women.
Metastaatilise rinnavähi uuringus võrreldi Caelyxit tavalise doksorubitsiiniga ühes põhiuuringus, milles osales kokku 509 naist.
For the full list of all side effects reported with Caelyx, see the package leaflet.
Caelyxi kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
For multiple myeloma, the effectiveness of the combination of Caelyx and bortezomib was compared with that of bortezomib alone in 646 patients.
Hulgimüeloomi ravis võrreldi Caelyxi ja bortesomiibi kombinatsiooni ainult bortesomiibiga 646 patsiendil.
Caelyx has been studied in a total of 2,512 patients in seven main studies.
Caelyxit uuriti kokku seitsmes põhiuuringus 2512 patsiendil.
Caelyx should not be used in people who may be hypersensitive (allergic) to doxorubicin hydrochloride or any of the other ingredients.
Caelyxit ei tohi kasutada patsiendid, kes võivad olla doksorubitsiinvesinikkloriidi või selle ravimi mis tahes muu koostisaine suhtes ülitundlikud (allergilised).
What is Caelyx?
Mis on Caelyx?
Caelyx is used in combination with bortezomib (another anticancer medicine).
Caelyxit kasutatakse koos bortesomiibiga (samuti vähiravim).
It cannot be interchanged with other medicines containing doxorubicin hydrochloride.
Caelyxit ei tohi asendada teiste doksorubitsiinvesinikkloriidi sisaldavate ravimitega.
Why has Caelyx been approved?
Miks Caelyx heaks kiideti?
Caelyx is used on its own for this disease;
Caelyxit kasutatakse selle haiguse ravimisel ainsa ravimina;
Caelyx is not recommended for patients whose spleen has been removed.
Caelyxit ei ole soovitatav kasutada eemaldatud põrnaga patsientidel.
For multiple myeloma, adding Caelyx to bortezomib increased the time until the disease got worse from 6.5 to 9.3 months.
Hulgimüeloomi ravis pikendas Caelyxi lisamine bortesomiibile haiguse süvenemiseni kulunud aega 6,5 kuult 9,3 kuuni.
For advanced ovarian cancer, Caelyx has been compared with topotecan (another anticancer medicine) in one study involving 474 women who had received platinum-based chemotherapy in the past.
Kaugelearenenud munasarjavähi ravis võrreldi Caelyxit topotekaaniga (samuti vähiravim) ühes uuringus, milles osales 474 naist, kes olid varem saanud plaatinal põhinevat keemiaravi.
What is the risk associated with Caelyx?
Mis riskid Caelyxiga kaasnevad?
Caelyx should be given under the supervision of a doctor who is qualified in the use of cytotoxic (cellkilling) medicines.
Caelyxit peab manustama tsütotoksilise (rakke hävitava) ravi väljaõppe saanud arsti järelevalve all.
For ovarian cancer, Caelyx was as effective as topotecan in extending time until the disease got worse.
Munasarjavähi ravis pikendas Caelyx haiguse süvenemiseni kulunud aega sama efektiivselt kui topotekaan.
The side effects with Caelyx depend on the type of cancer being treated.
Caelyxi kõrvalnähud sõltuvad ravitava vähi vormist.
Caelyx is concentrate to be made up into a solution for infusion (drip into a vein).
Caelyx on kontsentraat, millest valmistatakse infusioonilahus (veeni tilgutatav lahus).
Caelyx must not be used to treat Kaposi's sarcoma that could be treated effectively with ‘local' treatments that only affect the site of the tumour or with whole-body alfa interferon treatment.
Caelyxit ei tohi kasutada Kaposi sarkoomi ravimiseks, kui see allub paiksele ravile või süsteemsele alfainterferoonravile.
The active substance in Caelyx, doxorubicin hydrochloride, is a cytotoxic medicine that belongs to the group ‘anthracyclines'.
Caelyxi toimeaine doksorubitsiinvesinikkloriid on antratsükliinide rühma kuuluv tsütotoksiline ravim.
Caelyx accumulates in areas in the body where the blood vessels have an abnormal shape, such as within tumours, where its action is concentrated.
Caelyx koguneb organismis ebatavalise kujuga veresoontega piirkonda, kuhu ravimi toime koondub.
Treatment should be stopped or the dose reduced in patients who experience certain side effects or who have liver problems.
Teatavate kõrvalnähtude tekkimisel või maksaprobleemide korral tuleb patsiendi ravi katkestada või annust kohandada.
What benefit has Caelyx shown during the studies?
Milles seisneb uuringute põhjal Caelyxi kasulikkus?
How is Caelyx used?
Kuidas Caelyxit kasutatakse?
What is Caelyx used for?
Milleks Caelyxit kasutatakse?
How does Caelyx work?
Kuidas Caelyx toimib?
How has Caelyx been studied?
Kuidas Caelyxit uuriti?
In Caelyx, it is contained in ‘pegylated liposomes' (tiny fatty spheres that are coated with a chemical called polyethylene glycol).
Caelyxis sisaldub doksorubitsiinvesinikkloriid pegüleeritud liposoomides (keemilise aine polüetüleenglükooliga ümbritsetud tillukesed rasvakuulid), mistõttu aeglustub toimeaine lagunemine ja see püsib kauem vereringes.
Further information on Kineret can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Lisateave Kinereti kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Kineret received a marketing authorisation valid throughout the European Union on 8 March 2002.
Kineret on saanud müügiloa, mis kehtib kogu ELis, 8. märtsil 2002.
What measures are being taken to ensure the safe use of Kineret?
Mis meetmed võetakse, et tagada Kinereti ohutu kasutamine?
The improvement was maintained over a follow-up period of up to 60 months.
Paranemistulemused püsisid kuni 60 kuud kestnud jälgimisperioodi jooksul.
What is Kineret and what is it used for?
Mis on Kineret ja milleks seda kasutatakse?
The Agency recommended that Kineret be given marketing authorisation.
Amet soovitas anda Kinereti müügiloa.
• cryopyrin-associated periodic syndromes (CAPS).
• Krüopüriiniga seotud perioodiliste sündroomide (CAPS) ravi.
Other information about Kineret
Muu teave Kinereti kohta
Side effects reported with Kineret are carefully evaluated and any necessary action is taken to protect patients.
Kinereti kõrvalnähte hinnatakse hoolikalt ja patsientide kaitseks rakendatakse vajalikke meetmeid.
What are the risks associated with Kineret?
Mis riskid Kineretiga kaasnevad?
As for all medicines, data on the use of Kineret are continuously monitored.
Nagu kõigi ravimite puhul, teostatakse Kinereti kasutamise kohta pidevat järelevalvet.
Kineret has been studied in three main studies involving a total of 1,388 patients with rheumatoid arthritis.
Kinereti uuriti kolmes põhiuuringus, milles osales kokku 1388 reumatoidartriidiga patsienti.
Although patients with Still's disease had a higher risk of liver problems, this risk was considered to be outweighed by the medicine's benefits.
Kuigi Stilli tõvega patsientidel oli suurem risk maksaprobleemide tekkeks, peeti ravimi kasulikkust sellest riskist suuremaks.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Kineret have been included in the summary of product characteristics and the package leaflet.
Kinereti ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
Patients were given Kineret at a starting dose of 1 to 2 mg per kg body-weight daily, increased after a month if necessary.
Patsientidele manustati Kinereti algannuses 1-2 mg kehakaalu kg kohta ööpäevas, annust suurendati vajadusel ühe kuu pärast.
For more information about using Kineret, see the package leaflet or contact your doctor or pharmacist.
Lisateavet Kinereti kasutamise kohta vt pakendi infolehest või konsulteeri oma arsti või apteekriga.
However, because of the way the study was designed, the results were considered insufficient to support the use of the medicine on its own.
Uuringu ülesehituse tõttu ei peetud neid tulemusi aga piisavaks, et tõendada ravimi kasutamist ainuravimina.
The recommended dose of Kineret for rheumatoid arthritis is 100 mg once a day, given at around the same time each day.
Kinereti soovitatav annus reumatoidartriidi ravis on 100 mg üks kord ööpäevas ning seda manustatakse iga päev ligikaudu samal ajal.
All three studies compared the effectiveness of Kineret with that of placebo (a dummy treatment).
Kõigis kolmes uuringus võrreldi Kinereti efektiivsust platseebo (näiva ravimi) efektiivsusega.